Study Identifies Pathway to Start of Joint Disease

MAY 01, 2004

British researchers are confident that they have found a way to block a molecular mechanism that activates arthritis, and they believe that the discovery may lead to new drugs for the disease. Using cultured cartilage cells, the researchers found that blocking the enzyme protein kinase R halted the production of enzymes that break down the connective tissue and allow proteoglycan to be lost.

"We found that treating cartilage cells with tumor necrosis factor-alpha (TNF-alpha) and C2-ceramide stimulated the arthritic process by a number of mechanisms," said lead investigator Sophie Gilbert, PhD. In particular, the scientists witnessed an increase in the release of matrix metalloproteinase (MMP-1 and -9), 2 enzymes involved in arthritis. Furthermore, an increased loss of proteoglycans was noted when cartilage cells were treated with TNF-alpha and C2-ceramide, as well as an increased cartilage cell death, according to the researchers. (These findings were published recently in Arthritis Research & Therapy.)



SHARE THIS SHARE THIS
0
 

In Seniors: Consider CMV Serostatus
When Recommending Flu Vaccine

Older people who have cytomegalovirus seem to have less robust responses to the trivalent influenza vaccine than those who do not have CMV.


 

 

Conference Coverage
News from the year's biggest meetings


Pharmacist Education
Clinical features with downloadable PDFs


 

SIGN UP FOR THE PHARMACY TIMES NEWSLETTER
Personalize the information you receive by selecting targeted content and special offers.